Infarmed authorized innovative medicine for several types of cancer

Infarmed, the Portuguese Medicines and Health Products Authority, has authorized the use of the medicine pembrolizumab for the treatment of metastatic triple negative breast cancer, metastatic colorectal cancer, persistent cervical cancer, metastatic oesophageal cancer, renal cell carcinoma in adults and some cases of melanoma. Read more here

ELS can and will help you develop your new medicine, carry out feasibility studies and get your product regulated. If you would like to know more, please contact your ELS local consultant or through the email: info@elssolutions.pt

ELS Group

ELS Group brings together a team of highly specialized professionals with proven experience in regulatory frameworks and compliance in the pharmaceutical field.

Strategic consulting for the pharmaceutical, healthcare, food, and medtech industries.

Rely on experts to support your regulatory decisions and accelerate the growth of your products safely and efficiently.

Strategic consulting for the pharmaceutical, healthcare, food, and medtech industries.

Experts in pharmaceutical consulting, regulatory strategy, and market access to support your company with safety, compliance, and efficiency. Talk to a consultant.